Aligos Therapeutics

ALGSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$34.592 M

$5.59 +1.45%

Close of 7 Aug 2026

Revenue

$2.19M

#3421 by revenue

Earnings

-$24.2M

Loss-making

Shares outstanding

6,236,828

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#134ElutiaELUT$37.6M
#135Dyadic InternationalDYAI$36.4M
#136Aligos TherapeuticsALGS$34.6M
#137Estrella ImmunopharmaESLA$31.1M
#138Quince TherapeuticsQNCX$30.7M

Where these numbers come from

Share counts and financials for Aligos Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.